Can a Multiple Sleep Latency Test (MSLT) be performed in a patient who is currently taking a serotonin-norepinephrine reuptake inhibitor (SNRI), olanzapine, and the orexin antagonist daridorexant?

MSLT Should Not Be Performed With These Medications On Board

You should discontinue the SNRI, olanzapine, and daridorexant at least 2 weeks prior to MSLT testing (6 weeks for fluoxetine if applicable), as these medications significantly interfere with test validity and can produce false results. 1

Why These Medications Must Be Stopped

REM-Suppressing Antidepressants (SNRIs)

• SNRIs are REM-suppressing antidepressants (REMS-ADs) that fundamentally alter MSLT results
• Patients who taper off REMS-ADs before MSLT are 12 times more likely to demonstrate ≥2 sleep-onset REM periods (SOREMs) compared to those remaining on these medications 1
• Those who discontinue REMS-ADs show:
  • Shorter mean sleep latency (8.77 vs 10.21 minutes, p=0.009)
  • Higher odds of having ≥2 SOREMs (OR: 2.22) 1
• These differences persist even after controlling for confounding variables, indicating a true medication effect rather than underlying disease differences

Olanzapine

• As an atypical antipsychotic, olanzapine has acute depressive CNS effects 2
• This sedating property directly interferes with the MSLT's measurement of physiologic sleepiness
• The medication's CNS depression would artificially shorten sleep latency, potentially leading to false-positive results for hypersomnolence disorders

Daridorexant (Dual Orexin Receptor Antagonist)

• Daridorexant is a hypnotic medication that directly modulates the orexin/hypocretin system—the exact pathway disrupted in narcolepsy type 1 3
• Using an orexin antagonist during MSLT testing would fundamentally confound the test's ability to detect orexin deficiency
• This creates an obvious mechanistic conflict with the diagnostic purpose of the MSLT

Standard Withdrawal Protocol

The established protocol at major sleep centers requires:

• All antidepressants discontinued 2 weeks prior to MSLT (wherever clinically feasible)
• Fluoxetine specifically stopped 6 weeks prior due to its long half-life 1
• This same timeframe should apply to olanzapine and daridorexant given their CNS effects

Critical Considerations

If Medications Cannot Be Stopped

If psychiatric or medical stability precludes medication withdrawal:

• Do not proceed with MSLT testing as results will be uninterpretable
• Consider alternative diagnostic approaches (clinical diagnosis, actigraphy for 7-14 days to assess sleep patterns) 4
• Document clearly in the medical record why testing was deferred
• Any MSLT performed on these medications must include explicit documentation that results may be invalid and should not be used for definitive diagnosis 1

The MSLT's Known Limitations

• The MSLT already has poor test-retest repeatability, with diagnoses changing in approximately 29% of cases even under optimal conditions 5
• The test performs well only for narcolepsy type 1 with cataplexy (orexin deficiency)
• High false-positive rates occur for narcolepsy type 2 and idiopathic hypersomnia 6
• Adding medication confounders to an already imperfect test creates unacceptable diagnostic uncertainty

Urinary Drug Screening

• Perform urinary drug screening on all patients undergoing MSLT 7
• In one study, 16% of patients had positive drug screens (amphetamines, cannabinoids, opiates, benzodiazepines) that were not self-reported 7
• This ensures you're not missing undisclosed substances that would similarly invalidate results

Bottom Line

The combination of an SNRI, olanzapine, and daridorexant represents a triple threat to MSLT validity—REM suppression, CNS depression, and orexin system modulation. Proceeding with testing on these medications would produce results that are scientifically meaningless and clinically misleading, potentially leading to incorrect diagnoses and inappropriate treatment. The 2-week medication-free period (6 weeks for long-acting agents) is not optional; it's a prerequisite for valid testing.